• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Effectiveness of meningococcal conjugate vaccine wanes after 3-8 years

byMohammad MertabanandCordelia Ross
January 18, 2017
in Infectious Disease, Pediatrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The overall effectiveness of the meningococcal conjugate vaccine between 0 and 8 years post-vaccination was 69%.

2. The vaccine effectiveness (VE) was 79% at <1 year from vaccination, 69% at 1 to 3 years from vaccination, and 61% at 3 to 8 years from vaccination.

Evidence Rating Level: 3 (Fair)

Study Rundown: Being that the incidence of meningitis in the pediatric population has decreased significantly with the advent of the meningococcal conjugate vaccine, vaccine researchers use serological markers, rather than clinical symptoms, to document immunity. Data from early studies on VE of the meningococcal conjugated vaccine suggest that immunity may wane after several years of a single dose. This study aimed to examine VE and the duration of immunity of the meningococcal conjugate vaccine. Results demonstrated that the overall VE of a single dose of the vaccine was 69%, while the VE was 71% among adolescents with no underlying conditions. After the first year of vaccination, VE was 79%; at 1 to 3 years post-vaccination, VE was 69%; and 3 to 8 years post-vaccination, VE was 61%. Limitations of the study include a small sample size and possible reporting bias due to lack of verification of vaccination status. Nonetheless, this case-control study was critical, especially for immunization policymakers, and it was the data from this study that informed the policy decision to add a booster dose at the age of 16 years.

Click to read the study, published today in Pediatrics

Relevant Reading: Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.

In-Depth [case-control study]: Cases of meningococcal disease were identified through Active Bacterial Core surveillance (a population and laboratory based surveillance system coordinated by the CDC to the Emerging Infections Program) and MeningNet sites (local health departments funded to conduct enhanced meningococcal disease surveillance through the CDC). Eligibility included adolescents living in a surveillance area ≥ 11 years of age and born after January 1, 1986, at the time of illness. Cases were enrolled from January 1, 2006 through August 31, 2013 and were defined as those from which Neisseria meningitidis was isolated. These isolates were serogrouped and sent to the CDC for confirmation with PCR. Controls were eligible if they were within 2 years of the case and lived in the state or surveillance site at the time of illness onset of the case. Within this time period, 320 adolescents were identified as cases, but only 181 enrolled. A total of 199 controls were enrolled, where one or more of these controls were match to a case patient. The overall VE of a single dose of meningococcal disease was 69% (95% CI: 51 to 80%). VE was 79% in the first year after vaccination (95% CI: 49% to 91%), 69% at 1 to 3 years post-vaccination (95% CI: 44% to 83%), and 61% at 3 to 8 years after vaccination (95% CI: 25% to 79%).

RELATED REPORTS

Viral meningitis can be differentiated from abusive head trauma with demographic, history, and clinical findings

Lumbar puncture rates appropriately decline in children with simple febrile seizures

Success rates and timelines of recently studied viral vaccine candidates

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bacterial meningitisimmunizationmeningitis
Previous Post

Tonsillectomy may have short-term benefits in recurrent throat infection

Next Post

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

RelatedReports

Combined MRI and NIH stroke scores may predict stroke prognosis
Infectious Disease

Viral meningitis can be differentiated from abusive head trauma with demographic, history, and clinical findings

June 8, 2022
Social networks play key roles in parental vaccination decisions
Infectious Disease

Lumbar puncture rates appropriately decline in children with simple febrile seizures

October 21, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Success rates and timelines of recently studied viral vaccine candidates

December 7, 2020
Late pregnancy pertussis vaccination may boost passive immunity
Infectious Disease

Postmarket surveillance programs largest source of safety data triggering vaccine label changes

July 28, 2020
Next Post
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Cardiovascular risk factors related to brain volume and associated dementia

Ocrelizumab associated with lower progression rates for primary progressive multiple sclerosis: The ORATORIO trial

Brain lesions on MRI linked with subsequent increased stroke risk

Ocrelizumab decreases multiple sclerosis relapse rate compared to interferon beta-1a

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]
  • #VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
  • Tiotropium bromide safe and effective in treating early childhood wheezing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.